Drug details

Atorvaliq (atorvastatin)

type of Lipid-Lowering Agents, Statins, HMG-CoA Reductase Inhibitors

Atorvaliq (atorvastatin calcium) is an HMG-CoA reductase inhibitor (statin) indicated to reduce the risk of heart attack (myocardial infarction, or MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD; MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD; non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure (CHF), and angina in adults with clinically evident CHD; as an adjunct to diet to reduce low-density lipoprotein (LDL-C) in: adults with primary hyperlipidemia and in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH); as an adjunct to other LDL-C lowering therapies to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia; and as an adjunct to diet for the treatment of adults with primary dysbetalipoproteinemia and/or hypertriglyceridemia.

This drug may have the following side effects:

• nausea,
• diarrhea,
• joint pain,
• musculoskeletal pain,
• urinary tract infection (UTI),
• indigestion,
• runny or stuffy nose,
• pain in extremities,
• muscle spasms,
• insomnia, and
• throat pain.

The following drugs are related to Atorvaliq, either as a replacement or used together:

• Lipitor (atorvastatin calcium)
• Ezallor (rosuvastatin calcium tablets)
• Fenoglide (fenofibrate tablets)
• Trilipix (fenofibric acid capsules)
• Livalo (pitavastatin)
• Mevacor (lovastatin)
• Zypitamag (pitavastatin tablets for oral use)
• Pravachol (pravastatin sodium)
• Zocor (simvastatin)